Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy

Sponsor
Bausch & Lomb Incorporated
Study ID
NCT06618547
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Myopia

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TENEO 317 Model 2 excimer laser — DEVICE
    TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy

Study Details

A Study to Investigate the Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia with or without Astigmatism by Transepithelial Photorefractive Keratectomy

Key Dates

First listed
Oct 1, 2024
Start date
Nov 30, 2025
Status verified
Jun 2025
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
140 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TENEO 317 Model 2 excimer laser

Primary Outcome Measure

Maintenance of BCDVA - [ Time Frame: through study completion, an average of 1 year ]

Central Contacts

Related Studies